Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye

References

• YuJAscheCVFairchildCJThe economic burden of dry eye disease in the United States: a decision tree analysisCornea201130437938721045640
   PubMed Web of Science ®Google Scholar
• BronAJTomlinsonAFoulksGNRethinking dry eye disease: a perspective on clinical implicationsOcul Surf2014122 SupplS1S3124725379
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf200752759217508116
   PubMed Web of Science ®Google Scholar
• FriedmanNJImpact of dry eye disease and treatment on quality of lifeCurr Opin Ophthalmol201021431031620467319
   PubMed Web of Science ®Google Scholar
• Research in dry eye: report of the research subcommittee of the International Dry Eye WorkShop (2007)Ocul Surf20075217919317508121
   PubMed Web of Science ®Google Scholar
• WeiYAsbellPAThe core mechanism of dry eye disease is inflammationEye Contact Lens201440424825625390549
   PubMed Web of Science ®Google Scholar
• HollandEJLuchsJKarpeckiPMLifitegrast for the treatment of dry eye disease: results of a Phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)Ophthalmology20171241536028079022
   PubMed Web of Science ®Google Scholar
• SacchettiMMantelliFLambiaseAMastropasquaAMerloDBoniniSSystematic review of randomized clinical trials on topical ciclosporin A for the treatment of dry eye diseaseBr J Ophthalmol20149881016102224344232
   PubMed Web of Science ®Google Scholar
• AmesPGalorACyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidenceClin Investig (Lond)201553267285
   Google Scholar
• Restasis (cyclosporine ophthalmic emulsion) 0.05% full prescribing informationAllergan Inc Available from: https://www.allergan.com/assets/pdf/restasis_pi.pdfAccessed March 22, 2017
   Google Scholar
• American Academy of Ophthalmology Cornea/External Disease PanelPreferred Practice Pattern® GuidelinesDry Eye SyndromeSan Francisco, CAAmerican Academy of Ophthalmology
   Google Scholar
• StonecipherKGChiaJOnyenwenyiAVillanuevaLHollanderDAHealth claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patientsTher Clin Risk Manag2013940941524179335
   PubMed Web of Science ®Google Scholar
• AlvesMFonsecaECAlvesMFDry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategiesOcul Surf201311318119223838019
   PubMed Web of Science ®Google Scholar
• SallKStevensonODMundorfTKReisBLTwo multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study GroupOphthalmology2000107463163910768324
   PubMed Web of Science ®Google Scholar
• StevensonDTauberJReisBLEfficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study GroupOphthalmology2000107596797410811092
   PubMed Web of Science ®Google Scholar
• FoulksGNTopical cyclosporine for treatment of ocular surface diseaseInt Ophthalmol Clin2006464105122
   PubMedGoogle Scholar
• ChenMGongLSunXA comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trialJ Ocul Pharmacol Ther201026436136620698799
   PubMed Web of Science ®Google Scholar
• ZhouXQWeiRLTopical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysisCornea201433776076724815112
   PubMed Web of Science ®Google Scholar
• WanKHChenLJYoungALEfficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysisOcul Surf201513321322526045239
   PubMed Web of Science ®Google Scholar
• PerryHDSolomonRDonnenfeldEDEvaluation of topical cyclosporine for the treatment of dry eye diseaseArch Ophthalmol200812681046105018695097
   PubMedGoogle Scholar
• StonecipherKGTorkildsenGLOuslerGW3rdMorrisSVillanuevaLHollanderDAThe IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eyeClin Ophthalmol20161088789527257373
   PubMed Web of Science ®Google Scholar
• ScheinODTielschJMMunozBBandeen-RocheKWestSRelation between signs and symptoms of dry eye in the elderly. A population-based perspectiveOphthalmology19971049139514019307632
   PubMed Web of Science ®Google Scholar
• WilliamsonJFHuynhKWeaverMADavisRMPerceptions of dry eye disease management in current clinical practiceEye Contact Lens201440211111524508770
   PubMed Web of Science ®Google Scholar
• MillerKLWaltJGMinkDRMinimal clinically important difference for the ocular surface disease indexArch Ophthalmol201012819410120065224
   PubMedGoogle Scholar
• ParkYSongJSChoiCYYoonKCLeeHKKimHSA randomized multicenter study comparing 0.1%, 0.15%, and 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eyeJ Ocul Pharmacol Ther2017332667227929721
   PubMed Web of Science ®Google Scholar
• YangJMChoiWKimNYoonKCComparison of topical cyclosporine and diquafosol treatment in dry eyeOptom Vis Sci2015929e296e30226107023
   PubMed Web of Science ®Google Scholar
• KimECChoiJSJooCKA comparison of vitamin A and cyclosporine a 0.05% eye drops for treatment of dry eye syndromeAm J Ophthalmol2009147220613.e318848318
   PubMed Web of Science ®Google Scholar
• SaturniSBelliniFBraidoFRandomized controlled trials and real life studies. Approaches and methodologies: a clinical point of viewPulm Pharmacol Ther201427212913824468677
   PubMed Web of Science ®Google Scholar
• StonecipherKPerryHDGrossRHKerneyDLThe impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis siccaCurr Med Res Opin20052171057106316004673
   PubMed Web of Science ®Google Scholar
• ByunYSRhoCRChoKChoiJANaKSJooCKCyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance studyKorean J Ophthalmol201125636937422131772
   PubMedGoogle Scholar
• IaccheriBTorroniGCaginiCCorneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporineEye (Lond)201731578879428157225
   PubMed Web of Science ®Google Scholar
• AcheampongAAShackletonMTang-LiuDDDingSSternMEDeckerRDistribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogsCurr Eye Res19991829110310223652
   PubMed Web of Science ®Google Scholar
• DastjerdiMHHamrahPDanaRHigh-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimenCornea200928101091109619770713
   PubMed Web of Science ®Google Scholar
• GireAIKarakusSIngrodiSMAkpekEKFrequent dosing of topical cyclosporine A for severe ocular surface diseaseJ Ocular Pharmacol Ther2016323150154
   Web of Science ®Google Scholar
• TrattlerWKatsevDKerneyDSelf-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveysClin Ther200628111848185617213005
   PubMed Web of Science ®Google Scholar
• BarberLDPflugfelderSCTauberJFoulksGNPhase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 yearsOphthalmology2005112101790179416102833
   PubMed Web of Science ®Google Scholar
• BrownMMBrownGCBrownHCPeetJRothZValue-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndromeArch Ophthalmol2009127214615219204231
   PubMedGoogle Scholar
• RobertsCWCarnigliaPEBrazzoBGComparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eyeCornea200726780580917667613
   PubMed Web of Science ®Google Scholar
• MahFMilnerMYiuSDonnenfeldEConwayTMHollanderDAPERSIST: Physician’s evaluation of Restasis((R)) satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective reviewClin Ophthalmol201261971197623226002
   PubMedGoogle Scholar
• SheppardJDDonnenfeldEDHollandEJEffect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%Eye Contact Lens201440528929625083776
   PubMed Web of Science ®Google Scholar
• SheppardJDScoperSVSamudreSTopical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye diseaseJ Ocul Pharmacol Ther2011271232721133792
   PubMed Web of Science ®Google Scholar
• ByunYJKimTIKwonSMEfficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eyeCornea201231550951319730097
   PubMed Web of Science ®Google Scholar
• LeonardiAVan SettenGAmraneMEfficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trialEur J Ophthalmol201626428729627055414
   PubMed Web of Science ®Google Scholar
• Baiza-DuranLMedrano-PalafoxJHernandez-QuintelaELozano-AlcazarJAlaniz-de laOJA comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndromeBr J Ophthalmol201094101312131520679084
   PubMed Web of Science ®Google Scholar
• AgarwalPRupenthalIDModern approaches to the ocular delivery of cyclosporine ADrug Discov Today201621697798827080149
   PubMed Web of Science ®Google Scholar
• WilsonSEPerryHDLong-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatmentOphthalmology20071141767917070588
   PubMed Web of Science ®Google Scholar
• RaoSNTopical cyclosporine 0.05% for the prevention of dry eye disease progressionJ Ocul Pharmacol Ther201026215716420415623
   PubMed Web of Science ®Google Scholar
• RaoSNReversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawalJ Ocul Pharmacol Ther201127660360921999340
   PubMed Web of Science ®Google Scholar
• SuMYPerryHDBarsamAThe effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapyCornea201130101098110421407074
   PubMed Web of Science ®Google Scholar
• SongJSHyonJYLeeDCurrent practice pattern for dry eye patients in South Korea: a multicenter studyKorean J Ophthalmol201428211512124688253
   PubMedGoogle Scholar
• GalorAZhengDDArheartKLDry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006Cornea201231121403140722895158
   PubMed Web of Science ®Google Scholar
• DeveciHKobakSThe efficacy of topical 0.05% cyclosporine A in patients with dry eye disease associated with Sjogren’s syndromeInt Ophthalmol20143451043104824442759
   PubMed Web of Science ®Google Scholar
• PrabhasawatPTesavibulNKarnchanachetaneeCKasemsonSEfficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eyeJ Ocul Pharmacol Ther201329337237723289903
   PubMed Web of Science ®Google Scholar
• ArmanADemirserenDDTakmazTTreatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycyclineInt J Ophthalmol20158354454926086005
   PubMed Web of Science ®Google Scholar
• LelliGJJrMuschDCGuptaAFarjoQANairusTMMianSIOphthalmic cyclosporine use in ocular GVHDCornea200625663563817077652
   PubMed Web of Science ®Google Scholar
• JadidiKPanahiYEbrahimiAMafiMNejatFSahebkarATopical cyclosporine a for treatment of dry eye due to chronic mustard gas injuryJ Ophthalmic Vis Res20149441742225709764
   PubMedGoogle Scholar
• JadidiKEbrahimiAPanahiYTopical cyclosporine a for mustard gas induced ocular surface disordersJ Ophthalmic Vis Res2015101212526005548
   PubMedGoogle Scholar
• ChungYWOhTHChungSKThe effect of topical cyclosporine 0.05% on dry eye after cataract surgeryKorean J Ophthalmol201327316717123730108
   PubMedGoogle Scholar
• WillenCMMcGwinGLiuBOwsleyCRosenstielCEfficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyesEye Contact Lens2008341434518180683
   PubMed Web of Science ®Google Scholar
• PrabhasawatPTesavibulNMahawongWA randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunctionCornea201231121386139323135530
   PubMed Web of Science ®Google Scholar
• TorricelliAASanthiagoMRWilsonSETopical cyclosporine a treatment in corneal refractive surgery and patients with dry eyeJ Refract Surg201430855856425325897
   PubMed Web of Science ®Google Scholar
• SalibGMMcDonaldMBSmolekMSafety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusisJ Cataract Refract Surg200632577277816765793
   PubMed Web of Science ®Google Scholar
• EpsteinSPGadaria-RathodNWeiYMaguireMGAsbellPAHLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface diseaseExp Eye Res20131119510423567204
   PubMed Web of Science ®Google Scholar
• WeiYGadaria-RathodNEpsteinSAsbellPTear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating proceduresInvest Ophthalmol Vis Sci201354138327833624204044
   PubMed Web of Science ®Google Scholar
• SamburskyRPresence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eyeClin Ophthalmol2016102337234327920494
   PubMed Web of Science ®Google Scholar